Join us March 20 at 8pm ET to learn to recognize the amyloid-related imaging abnormalities (ARIA) associated with Alzheimer’s disease, including risk factors, clinical presentation and management. The webinar is sponsored by the ACR® Commission on Neuroradiology.
Earn 1.5 CME* and learn the optimal MRI protocols for detection, including the classic MRI findings and the clinical trial therapies. Learning Objectives:
- Describe the pathophysiology, risk factors, clinical presentation and management of patients with ARIA.
- Outline the MRI findings of ARIA-E and ARIA-H, optimize MRI protocols for ARIA detection, and implement the ARIA severity grading scale in clinical practice.
- Review clinical trial experience with disease-modifying AD medications, and FDA-approved agents (Aduhelm and Leqembi).
Jerome Barakos, MD
Director of Neuroimaging
California Pacific Medical Center, Sutter Health
Tammie L.S. Benzinger, MD, PhD
Professor of Radiology and Neurological Surgery
Medical Director of MRI services, Washington University School of Medicine
Ana M. Franceschi, MD, PhD
Associate Professor, Lenox Hill Hospital
John E. Jordan MD, MPP, FAC
Chair, ACR Commission on Neuroradiology
Christopher T. Whitlow, MD, PhD, MHA
Enterprise Academic Department Chair of Radiology
Greg Zaharchuk, MD, PhD
Professor of Radiology, Stanford University,
Division of Neuroimaging
*Physician Accreditation Statement The American College of Radiology® (ACR®) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physician Credit Designation Statement The American College of Radiology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Contact InformationFor information about the accreditation of this program, please contact the ACR at [email protected].